Sarepta Therapeutics Soars on Expanded Approval for Its Muscular Dystrophy Drug

By
Bill McColl
Bill McColl
Full Bio

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of the most notable news stories of the time.

Learn about our editorial policies
Published June 21, 2024
A Sarepta Therapeutics logo is seen on a smartphone and a PC screen

Pavlo Gonchar / SOPA Images / LightRocket via Getty Images

Key Takeaways

  • Sarepta Therapeutics shares jumped in premarket trading Friday, a day after the biotech firm received Food and Drug Administration approval for wider use of its drug to treat a rare muscle disease.
  • The company's Elevidys received traditional approval for those at least 4 years old with Duchenne muscular dystrophy who can walk, and accelerated approval to treat patients who cannot walk.
  • Sarepta said it is currently holding a Phase 3 trial to gain more FDA clearance for Elevidys' use.

Sarepta Therapeutics (SRPT) shares soared in premarket trading Friday, a day after the Food and Drug Administration (FDA) allowed expanded use of the biotech’s treatment for a rare muscle disease in children, which especially affects boys.

The company said its drug, Elevidys, was given traditional approval for patients who are at least 4 years old and suffer from Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene and can walk.

Phase 3 Trial for Non-Ambulatory Individuals With DMD Currently Underway

Sarepta said regulators granted accelerated approval for use in those who cannot walk, and continued approval “may be contingent upon verification of clinical benefit in a confirmatory trial.” The company added that a Phase 3 study to make that confirmation is currently underway.

The FDA gave accelerated approval for the gene-therapy medicine in 4- and 5-year-olds last year, despite some questions about its efficacy. 

Dr. Jerry Mendell, co-inventor of Elevidys and a senior adviser at Sarepta, said that the initial approval was a significant milestone, “and the expanded indication means clinicians now have a treatment option for the great majority of boys and young men living with Duchenne.”

Sarepta shares soared 35% to $167.00 an hour before the opening bell Friday after closing Thursday up 5.1% to $123.50.

SRPT

TradingView
Article Sources
Investopedia requires writers to use primary sources to support their work. These include white papers, government data, original reporting, and interviews with industry experts. We also reference original research from other reputable publishers where appropriate. You can learn more about the standards we follow in producing accurate, unbiased content in our editorial policy.

  1. Food and Drug Administration. “FDA Expands Approval of Gene Therapy for Patients with Duchenne Muscular Dystrophy.”

  2. Sarepta Therapeutics. "Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above."

Take the Next Step to Invest
×
The offers that appear in this table are from partnerships from which Investopedia receives compensation. This compensation may impact how and where listings appear. Investopedia does not include all offers available in the marketplace.